vs
Side-by-side financial comparison of CONSTELLIUM SE (CSTM) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
CONSTELLIUM SE is the larger business by last-quarter revenue ($2.2B vs $1.1B, roughly 2.0× PERRIGO Co plc). CONSTELLIUM SE runs the higher net margin — 5.1% vs -127.8%, a 132.9% gap on every dollar of revenue. PERRIGO Co plc produced more free cash flow last quarter ($148.6M vs $109.0M).
Constellium SE is an American-Swiss, French-based global manufacturer of aluminium rolled products, extruded products, and structural parts based on a large variety of advanced alloys. Constellium's C-TEC research center has been credited for advancing technology in the field of advanced aluminium alloy. Constellium primarily serves the aerospace, automotive, and packaging sectors. Large clients include Mercedes-Benz, Audi, BMW, Fiat Chrysler Automotive, Ford, Airbus, Boeing, and Bombardier.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
CSTM vs PRGO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.2B | $1.1B |
| Net Profit | $112.0M | $-1.4B |
| Gross Margin | — | 32.6% |
| Operating Margin | 7.5% | -116.0% |
| Net Margin | 5.1% | -127.8% |
| Revenue YoY | — | -2.5% |
| Net Profit YoY | — | -3093.9% |
| EPS (diluted) | $0.79 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.2B | $1.1B | ||
| Q3 25 | $2.2B | $1.0B | ||
| Q2 25 | $2.1B | $1.1B | ||
| Q1 25 | $2.0B | $1.0B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | $1.9B | $1.1B | ||
| Q1 24 | — | $1.1B |
| Q4 25 | $112.0M | $-1.4B | ||
| Q3 25 | $88.0M | $7.5M | ||
| Q2 25 | $36.0M | $-8.4M | ||
| Q1 25 | $37.0M | $-6.4M | ||
| Q4 24 | — | $-44.4M | ||
| Q3 24 | — | $-21.0M | ||
| Q2 24 | $76.0M | $-108.4M | ||
| Q1 24 | — | $2.0M |
| Q4 25 | — | 32.6% | ||
| Q3 25 | — | 36.1% | ||
| Q2 25 | — | 34.4% | ||
| Q1 25 | — | 37.6% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | — | 37.2% | ||
| Q2 24 | — | 37.0% | ||
| Q1 24 | — | 33.1% |
| Q4 25 | 7.5% | -116.0% | ||
| Q3 25 | 5.8% | 7.0% | ||
| Q2 25 | 2.7% | 4.3% | ||
| Q1 25 | 3.1% | 4.5% | ||
| Q4 24 | — | 10.0% | ||
| Q3 24 | — | 7.4% | ||
| Q2 24 | 5.4% | -2.5% | ||
| Q1 24 | — | -5.1% |
| Q4 25 | 5.1% | -127.8% | ||
| Q3 25 | 4.1% | 0.7% | ||
| Q2 25 | 1.7% | -0.8% | ||
| Q1 25 | 1.9% | -0.6% | ||
| Q4 24 | — | -3.9% | ||
| Q3 24 | — | -1.9% | ||
| Q2 24 | 3.9% | -10.2% | ||
| Q1 24 | — | 0.2% |
| Q4 25 | $0.79 | $-10.23 | ||
| Q3 25 | $0.62 | $0.05 | ||
| Q2 25 | $0.25 | $-0.06 | ||
| Q1 25 | $0.26 | $-0.05 | ||
| Q4 24 | — | $-0.32 | ||
| Q3 24 | — | $-0.15 | ||
| Q2 24 | $0.51 | $-0.79 | ||
| Q1 24 | — | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $120.0M | — |
| Total DebtLower is stronger | $1.9B | — |
| Stockholders' EquityBook value | $952.0M | $2.9B |
| Total Assets | $5.4B | $8.5B |
| Debt / EquityLower = less leverage | 2.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $120.0M | — | ||
| Q3 25 | $122.0M | $432.1M | ||
| Q2 25 | $133.0M | $454.2M | ||
| Q1 25 | $118.0M | $409.9M | ||
| Q4 24 | — | $558.8M | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $542.8M | ||
| Q1 24 | — | $658.5M |
| Q4 25 | $1.9B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.0B | — | ||
| Q1 25 | $1.9B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $952.0M | $2.9B | ||
| Q3 25 | $845.0M | $4.4B | ||
| Q2 25 | $780.0M | $4.5B | ||
| Q1 25 | $745.0M | $4.4B | ||
| Q4 24 | — | $4.3B | ||
| Q3 24 | — | $4.6B | ||
| Q2 24 | $796.0M | $4.5B | ||
| Q1 24 | — | $4.7B |
| Q4 25 | $5.4B | $8.5B | ||
| Q3 25 | $5.4B | $10.1B | ||
| Q2 25 | $5.4B | $10.1B | ||
| Q1 25 | $5.2B | $9.8B | ||
| Q4 24 | — | $9.6B | ||
| Q3 24 | — | $11.2B | ||
| Q2 24 | — | $10.4B | ||
| Q1 24 | — | $10.6B |
| Q4 25 | 2.00× | — | ||
| Q3 25 | 2.34× | — | ||
| Q2 25 | 2.53× | — | ||
| Q1 25 | 2.56× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $218.0M | $175.4M |
| Free Cash FlowOCF − Capex | $109.0M | $148.6M |
| FCF MarginFCF / Revenue | 5.0% | 13.4% |
| Capex IntensityCapex / Revenue | 5.0% | 2.4% |
| Cash ConversionOCF / Net Profit | 1.95× | — |
| TTM Free Cash FlowTrailing 4 quarters | $159.0M | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $218.0M | $175.4M | ||
| Q3 25 | $99.0M | $51.7M | ||
| Q2 25 | $114.0M | $75.9M | ||
| Q1 25 | $58.0M | $-64.5M | ||
| Q4 24 | — | $312.6M | ||
| Q3 24 | — | $42.2M | ||
| Q2 24 | $138.0M | $9.5M | ||
| Q1 24 | — | $-1.4M |
| Q4 25 | $109.0M | $148.6M | ||
| Q3 25 | $24.0M | $29.8M | ||
| Q2 25 | $37.0M | $56.7M | ||
| Q1 25 | $-11.0M | $-90.0M | ||
| Q4 24 | — | $274.9M | ||
| Q3 24 | — | $15.1M | ||
| Q2 24 | $54.0M | $-18.9M | ||
| Q1 24 | — | $-26.5M |
| Q4 25 | 5.0% | 13.4% | ||
| Q3 25 | 1.1% | 2.9% | ||
| Q2 25 | 1.8% | 5.4% | ||
| Q1 25 | -0.6% | -8.6% | ||
| Q4 24 | — | 24.2% | ||
| Q3 24 | — | 1.4% | ||
| Q2 24 | 2.8% | -1.8% | ||
| Q1 24 | — | -2.4% |
| Q4 25 | 5.0% | 2.4% | ||
| Q3 25 | 3.5% | 2.1% | ||
| Q2 25 | 3.7% | 1.8% | ||
| Q1 25 | 3.5% | 2.4% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | — | 2.5% | ||
| Q2 24 | 4.3% | 2.7% | ||
| Q1 24 | — | 2.3% |
| Q4 25 | 1.95× | — | ||
| Q3 25 | 1.13× | 6.89× | ||
| Q2 25 | 3.17× | — | ||
| Q1 25 | 1.57× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | — | -0.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSTM
| Packaging Rolled Products | $1.0B | 46% |
| Automotive Rolled Products | $318.0M | 14% |
| Aerospace Rolled Products | $270.0M | 12% |
| Transportation Industry Defense And Other Rolled Products | $232.0M | 11% |
| Automotive Extruded Products | $220.0M | 10% |
| Other Extruded Products | $132.0M | 6% |
| Specialty And Other Thin Rolled Products | $22.0M | 1% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
